SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cancer Immunology Immunotherapy

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1007/s00262-024-03806-2

License

CC-BY-NC-ND